Bio-rad Laboratories vs Qiagen
Bio-rad Laboratories is the larger business, with $2.58bn of revenue in fiscal 2025 against $2.09bn for Qiagen (1.2 times as much). Qiagen grew faster (5.7% against 0.7%). Bio-rad Laboratories kept more of each dollar of sales as profit: a net margin of 29.4% against 20.3%. Bio-rad Laboratories carries less debt relative to equity (16.2% against 43.8%).
| Latest fiscal year | Bio-rad LaboratoriesBIO, 2025 | QiagenQGEN, 2025 |
|---|---|---|
| Revenue | $2.58bn | $2.09bn |
| Revenue growth | 0.7% | 5.7% |
| Net income | $760m | $425m |
| Operating margin | 1.8% | 22.3% |
| Net margin | 29.4% | 20.3% |
| Return on equity | 10.8% | 11.6% |
| Free cash flow | $375m | $453m |
| Cash | $530m | $839m |
| Total debt | $1.21bn | $1.65bn |
| Debt to equity | 16.2% | 43.8% |
| Dividend per share | — | — |
| Dividend yield | — | 0.5% |
| Share buybacks | $296m | $280m |
| Employees | 7,450 | — |
| Market value | $10.02bn | $11.03bn |
| Price vs our value range | Above our value range | Above our value range |
| Moat score | 56 (Moderate) | 58 (Moderate) |
| Insider trades, 12 months | 0 buys, 2 sales | 0 buys, 0 sales |